About Acute Myeloid Leukemia (AML): There is an increasing unmet need in AML due to growing incidence, lac of new treatment options and an aging population. It is estimated that >70% of these patients have a poor outcome. Of the estimated 19,520 new patients in the US, only approximately 45% of these patients receive a hematopoietic stem cell transplant (SCT). While transplant offers benefit, more than half of these patients will have a relapse of their leukemia. For high risk patients, the one year mortality rate is 90%. There are no new treatment options available for patients with relapsed AML following SCT treatment or that had been transplant ineligible.
About Multiple Myeloma: Multiple Myeloma accounts for about 10% - 15% of all hematologic malignancies and primarily affects older individuals, with approximately 30,770 new cases. Though significant progress has been made for the treatment of myeloma patients extending survival beyond 7 years, the vast majority, however, relapse requiring further treatment. Similar to activities demonstrated by adoptive cellular therapies in other cancers, T-cell based treatments have the potential to shift the paradigm in myeloma.
About AIM™ nanoparticle (ex vivo): ): AIM™ nanoparticle (ex vivo) is a multi-tumor associated antigen T cell product. PBMCs from a donor or the patient are used to enrich and expand tumor specific CD8+ T cells using NexImmune’s proprietary AIM™ technology.
About AIM™ nanoparticle (direct injection): AIM™ nanoparticle (direct injection) is a PLGA-PEG based nanoparticle decorated with HLA presenting disease-relevant antigens and humanized stimulatory ligands. To enhance engagement with targeted T cell subtypes, AIM™ nanoparticles can be designed to increase trafficking to lymph nodes. AIM™ nanoparticle (direct injection) is an ideal application for rapid loading and delivery of known tumor associated antigens of choice or neoantigens corresponding to individual patients.